Loading
Led the DRUP trial giving off-label targeted drugs by genomic match, and developed organoid-based testing.
Emile Voest is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL). His specialisms are precision oncology, organoids and off-label drug access trials, and he works with patient-derived organoids, whole-genome sequencing and functional ex vivo drug testing. He founded the Dutch DRUP trial, which gives off-label targeted drugs by genomic match, and the Hartwig Medical Foundation whole-genome sequencing programme. His Nature paper on the Drug Rediscovery protocol described how this approach expands the use of existing anticancer drugs. He also developed patient-derived organoid co-cultures to test how tumours respond to immunotherapy. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs | Nature | 2019 |
| NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients | New England Journal of Medicine | 2024 |
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Netherlands Cancer Institute (NKI-AvL), Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.